Acurx Pharmaceuticals annual stock-based compensation
2020
2021
2022
2023
2024
2025
Acurx Pharmaceuticals Stock-Based Compensation Growth & History (ACXP)
Acurx Pharmaceuticals's stock-based compensation was $1.2M for fiscal 2025.
View full Acurx Pharmaceuticals company overviewAcurx Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.2M | −$1.4M | −52.06% |
| 2024 | 2024-12-31 | $2.6M | −$604,624 | −18.86% |
| 2023 | 2023-12-31 | $3.2M | $334,846 | +11.66% |
| 2022 | 2022-12-31 | $2.9M | −$2.3M | −44.29% |
| 2021 | 2021-12-31 | $5.2M | $4.5M | +640.80% |
| 2020 | 2020-12-31 | $695,833 | — | — |
Acurx Pharmaceuticals quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $200,537 | −$123,679 | −38.15% |
| Q1 2026 | 2026-03-31 | $258,287 | −$75,311 | −22.58% |
| Q4 2025 | 2025-12-31 | $294,794 | −$50,397 | −14.60% |
| Q3 2025 | 2025-09-30 | $294,793 | −$50,398 | −14.60% |
| Q2 2025 | 2025-06-30 | $324,216 | −$692,782 | −68.12% |
| Q1 2025 | 2025-03-31 | $333,598 | −$560,925 | −62.71% |
| Q4 2024 | 2024-12-31 | $345,191 | −$488,094 | −58.57% |
| Q3 2024 | 2024-09-30 | $345,191 | −$488,094 | −58.57% |
| Q2 2024 | 2024-06-30 | $1.0M | $210,513 | +26.10% |
| Q1 2024 | 2024-03-31 | $894,523 | $161,051 | +21.96% |
| Q4 2023 | 2023-12-31 | $833,285 | $136,320 | +19.56% |
| Q3 2023 | 2023-09-30 | $833,285 | $136,320 | +19.56% |
| Q2 2023 | 2023-06-30 | $806,485 | $89,803 | +12.53% |
| Q1 2023 | 2023-03-31 | $733,472 | −$27,597 | −3.63% |
| Q4 2022 | 2022-12-31 | $696,965 | $24,329 | +3.62% |
| Q3 2022 | 2022-09-30 | $696,965 | −$1.4M | −66.34% |
| Q2 2022 | 2022-06-30 | $716,682 | −$1.5M | −67.71% |
| Q1 2022 | 2022-03-31 | $761,069 | $569,402 | +297.08% |
| Q4 2021 | 2021-12-31 | $672,636 | — | — |
| Q3 2021 | 2021-09-30 | $2.1M | $1.9M | +1083.22% |
| Q2 2021 | 2021-06-30 | $2.2M | $2.1M | +1231.87% |
| Q1 2021 | 2021-03-31 | $191,667 | — | — |
| Q3 2020 | 2020-09-30 | $175,000 | — | — |
| Q2 2020 | 2020-06-30 | $166,666 | — | — |
Acurx Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Acurx Pharmaceuticals's stock-based compensation increased from $695,833 to $1.2M, a change of $551,568. The latest reported quarter, Q2 2026, shows $200,537.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Acurx Pharmaceuticals source filings ↗